#Medchem @merckgroup former @bayerpharma interested in #cancer #kinaseinhibitors #degraders only personal views Reviewer @drughunter
Darmstadt, Germany
Joined November 2017
- Tweets923
- Following580
- Followers901
- Likes2.7K
Julien Lefranc retweeted
Molecule One-Pager: ARV-471 (vepdegestrant)
This molecule one-pager includes links to key presentations, publications, patents, preclinical and clinical PK data summaries, and more.
One-pager link: drughunters.com/3YoQR8v
Julien Lefranc retweeted
BMS-986365: A Next-Generation Oral AR Heterobifunctional Degrader for Drug-Resistant Prostate Cancer
This full case study details how BMS-986365 was engineered to have low intrinsic agonism and exert direct antagonism of WT AR and more!
Full Article: drughunters.com/4dIhx9d
Julien Lefranc retweeted
If he could have dinner with a well-known historic figure, who would @AlexBismuto invite? @bismutolab @unibonn Find out on his #IntroducingAngewandte page xitter.cf/16467437/status/180278… onlinelibrary.wiley.com/doi/…
Light-Dependent Reactivity of Heavy Pnictogen Double Bonds (Alessandro Bismuto and co-workers) @bismutolab #openaccess onlinelibrary.wiley.com/doi/…
Julien Lefranc retweeted
There is still time to register for the Thematic meeting from @SCT_asso: Targeted Protein Degradation Gentilly @SanofiFR (Paris) with a fantastic program. You can click under the following link sct-asso.fr/tpdmeeting
Julien Lefranc retweeted
Come and join us, what are you waiting for?! We have a fully funded PhD position @UniBonn on Sb- and Bi-luminescent compounds🧪. The deadline is April 24, interested candidate should send the application (cover letter and CV) to bismulab@gmail.com
Julien Lefranc retweeted
🔥🔥“TPD one-day Thematic meeting” in Paris (SANOFI) May 30th 2024 @SCT_asso : register open bit.ly/4arCfZd
@DanNomura
Dr. M. Schroeder
@fmorreale_ester
Prof. N. Thomä
@iDikic2
Dr. M. Koegl
Dr. S. Jegham
Dr. K. McAulay
Prof. A.-S. Voisin-Chiret
Julien Lefranc retweeted
Molecules of the Month – Feb. 2024
Actelion revealed the discovery story of nivasorexant, a selective orexin-1 receptor antagonist, which completed a Ph. II clinical trial in binge-eating disorder.
Check out our other top molecules from Feb.!
Article | drughunters.com/3vbzEDY
Julien Lefranc retweeted
We have an open position for a postdoc in our Medicinal Chemistry & Drug Design department @merckgroup: If you are equally excited about chemistry automation and about applying synthetic chemistry to answer biological questions, check out this highly attractive opportunity!
Julien Lefranc retweeted
RT, please 😀We are starting the interviews next month! Still time to apply to join our ⚡ElectraTeam⚡! One PhD in collaboration with @GSK @PdCyclist/
@DPSynthChemist:
findaphd.com/phds/project/gs… and another one funded by the @LeverhulmeTrust: findaphd.com/phds/project/le… #RealTimeChem
Julien Lefranc retweeted
Deadline is coming up for nomination to the @EuroMedChem 2024 awards, 31 Jan 2024: efmc.info/awards be sure to nominate someone you admire! 🏆
Julien Lefranc retweeted
To do drug discovery well, we must all be pharmacologists 💊
(At least a little)
Julien Lefranc retweeted
We are currently also recruiting into a postdoc position into our AI & computational technologies team (within Medicinal Chemistry & Drug Design): Check out this job at Merck Group: Postdoctoral Fellow - Deep-Learning In Early Drug Discovery (All Genders) linkedin.com/jobs/view/37601…
Julien Lefranc retweeted
We have an opening in our antibody-drug conjugates (ADC) chemistry team: Principal Scientist (all genders) - Merck KGaA, Darmstadt, Germany. Check out the link below! merckgroup.com/en/careers/jo…
Julien Lefranc retweeted
KT-474 Brings IRAK4 Back | drughunters.com/3t2PXBI
Kymera's KT-474 is the first oral degrader to demonstrate activity in clinical trials outside cancer. This article highlights several reasons why Kymera’s KT-474 program is likely to be considered a “classic in drug discovery.”
Julien Lefranc retweeted
We will be advertising a PhD position for one of the craziest and most exciting ideas involving a lot of ⚡️! Stay tuned and feel free to RT or get in touch if you’re looking for a #PhD #scholarship (UK/EU settled/IE students).
Julien Lefranc retweeted
Very gratifying to see this work published, was a really fun team to work with and I learned a lot from all.
biorxiv.org/content/10.1101/…
Julien Lefranc retweeted
We have an open postdoctoral position to work in catalytic carbyne transfer and late-stage applications. Join us ! careers.iciq.org/jobs/301920…
Julien Lefranc retweeted
"eHydrogenation: be lazy, yet selective!": No need for hydrogen, metals, degassing, drying, or supporting electrolytes! Mix everything, turn the current on, and forget about it. Come back, and you'll get your hydrogenated product! #Easy #Hydrogenation #OpenAccess #RealTimeChem
eHydrogenation: Hydrogen-free Electrochemical Hydrogenation (Kevin Lam and co-workers) @KLchemistry @jamiewalsh1999 @CK_echem #openaccess onlinelibrary.wiley.com/doi/…
